# Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.

> **NCT05145348** · — · UNKNOWN · sponsor: **UMC Utrecht** · enrollment: 640 (estimated)

## Conditions studied

- Down Syndrome
- SARS-CoV-2 Vaccination

## Interventions

- **BIOLOGICAL:** Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)

## Key facts

- **NCT ID:** NCT05145348
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-03
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 640 (ESTIMATED)
- **Last updated:** 2021-12-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145348, "Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05145348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*